Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
This acquisition enables MTD to open new, strategic markets
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated